公开(公告)号：US20060189632A1

公开(公告)日：2006-08-24

申请号：US10547080

申请日：2004-03-01

申请人： Kenichiro Kataoka ,  Naotaka Suzuki ,  Tomomi Kosugi ,  Minoru Imai ,  Hiroaki Makino ,  Mika Takakuwa ,  Gen Unoki ,  Aiko Fujino ,  Yasuhiro Oue ,  Yuko Yamakoshi ,  Satoshi Sugiura ,  Robert Mitchell ,  James Simpson ,  John Harris ,  Joelle Le

发明人： Kenichiro Kataoka ,  Naotaka Suzuki ,  Tomomi Kosugi ,  Minoru Imai ,  Hiroaki Makino ,  Mika Takakuwa ,  Gen Unoki ,  Aiko Fujino ,  Yasuhiro Oue ,  Yuko Yamakoshi ,  Satoshi Sugiura ,  Robert Mitchell ,  James Simpson ,  John Harris ,  Joelle Le

IPC分类号： A61K31/519 ,  C07D487/04

CPC分类号： C07D487/04

摘要： The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent kinase inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for a protein kinase mediated disorder in which kinase is implicated, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth.

公开(公告)号：US07557110B2

公开(公告)日：2009-07-07

申请号：US10547080

申请日：2004-03-01

申请人： Kenichiro Kataoka ,  Naotaka Suzuki ,  Tomomi Kosugi ,  Minoru Imai ,  Hiroaki Makino ,  Mika Takakuwa ,  Gen Unoki ,  Aiko Fujino ,  Yasuhiro Oue ,  Yuko Yamakoshi ,  Satoshi Sugiura ,  Robert Dale Mitchell ,  James Donald Simpson ,  John Clifford Harris ,  Joelle Le

发明人： Kenichiro Kataoka ,  Naotaka Suzuki ,  Tomomi Kosugi ,  Minoru Imai ,  Hiroaki Makino ,  Mika Takakuwa ,  Gen Unoki ,  Aiko Fujino ,  Yasuhiro Oue ,  Yuko Yamakoshi ,  Satoshi Sugiura ,  Robert Dale Mitchell ,  James Donald Simpson ,  John Clifford Harris ,  Joelle Le

IPC分类号： C07D487/04 ,  A61K31/519

CPC分类号： C07D487/04

摘要： The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent kinase inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for a protein kinase mediated disorder in which kinase is implicated, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth.

摘要翻译： 由式I表示的吡唑并[1,5-a]嘧啶衍生物及其药学上可接受的盐表现出优异的激酶抑制活性。 因此，包含化合物作为有效成分的药物预期可用作其中涉及激酶的蛋白激酶介导的病症的治疗或预防剂，例如炎性疾病，自身免疫疾病，破坏性骨病，癌症和/或肿瘤生长。

公开(公告)号：US07557113B2

公开(公告)日：2009-07-07

申请号：US10928969

申请日：2004-08-26

申请人： Takaharu Tsutsumi ,  Satoshi Sugiura ,  Masahiro Koga ,  Yoshiyuki Matsumoto ,  Toshihiro Ishii ,  Akira Nakano ,  Gen Unoki ,  Yuri Sakai ,  Reiko Takarada ,  Hiroko Ogawa

发明人： Takaharu Tsutsumi ,  Satoshi Sugiura ,  Masahiro Koga ,  Yoshiyuki Matsumoto ,  Toshihiro Ishii ,  Akira Nakano ,  Gen Unoki ,  Yuri Sakai ,  Reiko Takarada ,  Hiroko Ogawa

IPC分类号： C07D487/04 ,  A61K31/519 ,  A61P35/04 ,  A61P25/18

CPC分类号： C07D487/04

摘要： A compound having GSK-3 inhibitory activity. A1 and A3 are a single bond, an aliphatic hydrocarbon group; A2 and A4 are a single bond, CO, COO, CONR, O, OCO, NR, NRCO, NRCOO, etc.; G1 is a single bond, an aliphatic hydrocarbon, aromatic hydrocarbon, heterocyclic; G2 is H, an aliphatic hydrocarbon, an alicyclic hydrocarbon, an aromatic hydrocarbon, heterocyclic; A5 is a single bond, NR; R2 is H, halogen, an aliphatic hydrocarbon, alicyclic hydrocarbon, aromatic hydrocarbon, heterocyclic; A6 is a single bond, NR, CO, NRCO, NRCONR, CONR, COO, O, etc.; R3 is H, halogen, nitro, saturated aliphatic hydrocarbon, alicyclic hydrocarbon, aromatic hydrocarbon, heterocyclic; and R3 may be a trimethylsilyl, formyl, acyl, carboxyl, alkoxylcarbonyl, carbamoyl, alkylcarbamoyl, or cyano group when A6 is CR═CR or C≡C, wherein R is H or an lower aliphatic hydrocarbon group.

摘要翻译： 具有GSK-3抑制活性的化合物。 A1和A3是单键，脂族烃基; A2和A4是单键，CO，COO，CONR，O，OCO，NR，NRCO，NRCOO等; G1是单键，脂族烃，芳烃，杂环; G 2是H，脂族烃，脂环烃，芳烃，杂环; A5是单键，NR; R2是H，卤素，脂族烃，脂环族烃，芳烃，杂环; A6是单键，NR，CO，NRCO，NRCONR，CONR，COO，O等; R3是H，卤素，硝基，饱和脂肪烃，脂环族烃，芳烃，杂环; 当A6是CR-CR或C≡C时，R3可以是三甲基甲硅烷基，甲酰基，酰基，羧基，烷氧基羰基，氨基甲酰基，烷基氨基甲酰基或氰基，其中R是H或低级脂族烃基。

公开(公告)号：US20060160831A1

公开(公告)日：2006-07-20

申请号：US10928969

申请日：2004-08-26

申请人： Takaharu Tsutsumi ,  Satoshi Sugiura ,  Masahiro Koga ,  Yoshiyuki Matsumoto ,  Toshihiro Ishii ,  Akira Nakano ,  Gen Unoki ,  Yuri Sakai ,  Reiko Takarada ,  Hiroko Ogawa

发明人： Takaharu Tsutsumi ,  Satoshi Sugiura ,  Masahiro Koga ,  Yoshiyuki Matsumoto ,  Toshihiro Ishii ,  Akira Nakano ,  Gen Unoki ,  Yuri Sakai ,  Reiko Takarada ,  Hiroko Ogawa

IPC分类号： A61K31/519 ,  C07D487/02

CPC分类号： C07D487/04

摘要： A compound having GSK-3 inhibitory activity. A1 and A3 are a single bond, an aliphatic hydrocarbon group; A2 and A4 are a single bond, CO, COO, CONR, O, OCO, NR, NRCO, NRCOO, etc.; G1 is a single bond, an aliphatic hydrocarbon, aromatic hydrocarbon, heterocyclic; G2 is H, an aliphatic hydrocarbon, an alicyclic hydrocarbon, an aromatic hydrocarbon, heterocyclic; A5 is a single bond, NR; R2 is H, halogen, an aliphatic hydrocarbon, alicyclic hydrocarbon, aromatic hydrocarbon, heterocyclic; A6 is a single bond, NR, CO, NRCO, NRCONR, CONR, COO, O, etc.; R3 is H, halogen, nitro, saturated aliphatic hydrocarbon, alicyclic hydrocarbon, aromatic hydrocarbon, heterocyclic; and R3 may be a trimethylsilyl, formyl, acyl, carboxyl, alkoxylcarbonyl, carbamoyl, alkylcarbamoyl, or cyano group when A6 is CR═CR or C≡C, wherein R is H or an lower aliphatic hydrocarbon group.

摘要翻译： 具有GSK-3抑制活性的化合物。 A 1和A 3是单键，脂族烃基; A <2>和A 4是单键，CO，COO，CONR，O，OCO，NR，NRCO，NRCOO等; G 1是单键，脂族烃，芳族烃，杂环基; G 2是H，脂族烃，脂环烃，芳族烃，杂环基; A <5>是单键NR; R 2是H，卤素，脂族烃，脂环烃，芳烃，杂环; NR 6 CO 2，NRCO，NRCONR，CONR，COO，O等单键。 R 3是H，卤素，硝基，饱和脂族烃，脂环烃，芳族烃，杂环; 当A 6是CR-CR或C≡C时，R 3可以是三甲基甲硅烷基，甲酰基，酰基，羧基，烷氧基羰基，氨基甲酰基，烷基氨基甲酰基或氰基，其中 R是H或低级脂族烃基。

公开(公告)号：US20050153992A1

公开(公告)日：2005-07-14

申请号：US10928600

申请日：2004-08-26

申请人： Takaharu Tsutsumi ,  Satoshi Sugiura ,  Masahiro Koga ,  Yoshiyuki Matsumoto ,  Toshihiro Ishii ,  Akira Nakano ,  Gen Unoki ,  Yuri Sakai ,  Reiko Takarada ,  Hiroko Ogawa

发明人： Takaharu Tsutsumi ,  Satoshi Sugiura ,  Masahiro Koga ,  Yoshiyuki Matsumoto ,  Toshihiro Ishii ,  Akira Nakano ,  Gen Unoki ,  Yuri Sakai ,  Reiko Takarada ,  Hiroko Ogawa

IPC分类号： A61K31/519 ,  A61P3/10 ,  A61P17/14 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07D487/02 ,  C07D487/04

CPC分类号： A61K31/519 ,  C07D487/04

摘要： A compound having GSK-3 inhibiting function. A1 and A3 are a single bond, an aliphatic hydrocarbon group; A2 and A4 are a single bond, CO, COO, CONR, O, OCO, NR, NRCO, NRCOO, etc.; G1 is a single bond, an aliphatic hydrocarbon, aromatic hydrocarbon, heterocyclic; G2 is a hydrogen atom, an aliphatic hydrocarbon, an alicyclic hydrocarbon, an aromatic hydrocarbon, heterocyclic; A5 is a single bond, NR; R2 is H, halogen, an aliphatic hydrocarbon, alicyclic hydrocarbon, aromatic hydrocarbon, heterocyclic; A6 is a single bond, NR, CO, NRCO, NRCONR, CONR, COO, O, etc.; R3 is H, halogen, nitro, saturated aliphatic hydrocarbon, alicyclic hydrocarbon, aromatic hydrocarbon, heterocyclic; and when A6 is CR═CR or C≡C; R3 may be a trimethylsilyl, formyl, acyl, carboxyl, alkoxylcarbonyl, carbamoyl, alkylcarbamoyl or cyano group; and R is H or an aliphatic hydrocarbon group.

摘要翻译： 具有GSK-3抑制功能的化合物。 A 1和A 3是单键，脂族烃基; A <2>和A 4是单键，CO，COO，CONR，O，OCO，NR，NRCO，NRCOO等; G 1是单键，脂族烃，芳族烃，杂环基; G 2是氢原子，脂族烃，脂环烃，芳族烃，杂环基; A <5>是单键NR; R 2是H，卤素，脂族烃，脂环烃，芳烃，杂环; NR 6 CO 2，NRCO，NRCONR，CONR，COO，O等单键。 R 3是H，卤素，硝基，饱和脂族烃，脂环烃，芳族烃，杂环; 当A <6> CR-CR或C≡C时; R 3可以是三甲基甲硅烷基，甲酰基，酰基，羧基，烷氧基羰基，氨基甲酰基，烷基氨基甲酰基或氰基; R为H或脂族烃基。

公开(公告)号：US08909321B2

公开(公告)日：2014-12-09

申请号：US12277441

申请日：2008-11-25

申请人： Satoshi Sugiura

发明人： Satoshi Sugiura

IPC分类号： A61B5/05 ,  G01V3/00 ,  G01R33/567 ,  G01R33/563 ,  G01R33/54 ,  A61B5/055 ,  A61B6/00 ,  A61B5/024

CPC分类号： A61B5/055 ,  A61B5/0037 ,  A61B5/024 ,  A61B6/503 ,  A61B6/504 ,  G01R33/543 ,  G01R33/546 ,  G01R33/56325 ,  G01R33/5635 ,  G01R33/56366 ,  G01R33/5676

摘要： A diagnostic imaging apparatus includes a ventricular volume-variation measuring unit that measures sequential variations in a size of a ventricle within at least one heart beat, from images of a heart scanned in each of a plurality of time phases; a scanning-condition setting unit that specifies a time phase of little cardiac motion based on variations in the size of the ventricle measured by the ventricular volume-variation measuring unit, and sets scanning conditions so as to collect data in the specified time phase; and an imaging unit that collects data based on the scanning conditions set by the scanning-condition setting unit, and reconstructs an image from the collected data.

摘要翻译： 诊断成像装置包括心室体积变化测量单元，其测量在多个时间段中的每一个中扫描的心脏的图像中的至少一个心跳内的心室的尺寸的顺序变化; 扫描条件设置单元，其基于由心室体积变化测量单元测量的脑室尺寸的变化来指定小心脏运动的时间相位，并且设置扫描条件以便以指定的时间段收集数据; 以及成像单元，其基于由扫描条件设置单元设置的扫描条件来收集数据，并且从所收集的数据重建图像。

公开(公告)号：US08830801B2

公开(公告)日：2014-09-09

申请号：US13984442

申请日：2012-02-17

申请人： Katsumi Yoshizawa ,  Satoshi Sugiura ,  Takayuki Kasuya

发明人： Katsumi Yoshizawa ,  Satoshi Sugiura ,  Takayuki Kasuya

IPC分类号： G11B11/00

CPC分类号： G11B13/08 ,  F21K9/60 ,  G11B5/02 ,  G11B5/4886 ,  G11B9/1409 ,  G11B2005/0021

摘要： A recording apparatus records information onto a recording medium. The recording apparatus is provided with: a near-field light device; and a control unit for controlling the near-field light device. The near-field light device is provided with: a light source; a quantum dot structure which is laminated on the light source; a plurality of quantity dots which are included in the quantity dot structure and each of which generates near-field light on the basis of light emitted from the light source; and an output end which is configured to output at least one portion of energy of the near-field light to the exterior of the quantity dot structure. The control unit of the recording apparatus controls the light source to emit the light upon recording the information, thereby increasing temperature of a region of the recording medium based on a size of the output end.

摘要翻译： 记录装置将信息记录到记录介质上。 记录装置设有：近场光装置; 以及用于控制近场光装置的控制单元。 近场灯装置设有：光源; 层叠在光源上的量子点结构; 多个量点包括在数量点结构中，并且每个点基于从光源发出的光产生近场光; 以及输出端，其被配置为将近场光的至少一部分能量输出到数量点结构的外部。 记录装置的控制单元在记录信息时控制光源发光，从而基于输出端的尺寸增加记录介质的区域的温度。

公开(公告)号：US08560049B2

公开(公告)日：2013-10-15

申请号：US13283948

申请日：2011-10-28

申请人： Yoshimori Kassai ,  Mitsue Miyazaki ,  Satoshi Sugiura

发明人： Yoshimori Kassai ,  Mitsue Miyazaki ,  Satoshi Sugiura

IPC分类号： A61B5/05

CPC分类号： A61B5/055 ,  A61B5/0456 ,  A61B5/7207 ,  A61B5/7257 ,  A61B5/7285 ,  G01R33/4828 ,  G01R33/5605 ,  G01R33/5607 ,  G01R33/5615 ,  G01R33/5617 ,  G01R33/5635 ,  G01R33/5673

摘要： A magnetic resonance imaging (MRI) system obtains an MR image of an object. The system detects an ECG signal and performs a pulse sequence of RF gradient magnetic fields toward the object. Imaging defined by the pulse sequence is longer in temporal length than one heartbeat. The system further acquires an MR signal from the object in response to performance of the pulse sequence and produces the MR image based on the acquired MR signal. Also possible are: a plurality of divided MT pulses instead of the conventional single MT pulse, an SE-system pulse sequence having a shorter echo train spacing, and the generation of sounds by applying gradient pulses incorporated in an imaging pulse sequence so as to automatically instruct a patient to perform an intermittent breath hold.

公开(公告)号：US08125222B2

公开(公告)日：2012-02-28

申请号：US12521806

申请日：2009-03-03

申请人： Satoshi Sugiura

发明人： Satoshi Sugiura

IPC分类号： G01V3/00

CPC分类号： G01R33/54 ,  G01R33/546

摘要： A storage unit stores a parameter list that defines a method of creating scanning conditions for a preparation scan from scanning conditions set for a main scan, with respect to each type of scanning. A scanning-condition edit/scan positioning unit receives an operation of selecting a type of a preparation scan, and when the operation of selecting the type of the preparation scan is received, the scanning-parameter limit calculating unit acquires the parameter list corresponding to the type of the preparation scan, from among the parameter lists stored by the storage unit, creates scanning conditions for the preparation scan from scanning conditions set for a main scan based on the parameter list corresponding to the type of the preparation scan. The pulse-sequence execution-data creating unit then causes execution of the preparation scan based on the created scanning conditions.

摘要翻译： 存储单元存储参数列表，该参数列表针对每种扫描类型定义从为主扫描设置的扫描条件创建用于准备扫描的扫描条件的方法。 扫描条件编辑/扫描定位单元接收选择准备扫描的类型的操作，并且当接收到选择准备扫描的类型的操作时，扫描参数限制计算单元获取与 基于与准备扫描的类型对应的参数列表，从存储单元存储的参数列表中的准备扫描的类型从为主扫描设置的扫描条件创建用于准备扫描的扫描条件。 脉冲序列执行数据创建单元然后基于所创建的扫描条件执行准备扫描。

公开(公告)号：US07647086B2

公开(公告)日：2010-01-12

申请号：US10678309

申请日：2003-10-06

申请人： Mitsue Miyazaki ,  Satoshi Sugiura

发明人： Mitsue Miyazaki ,  Satoshi Sugiura

IPC分类号： A61B5/05

CPC分类号： G01R33/56308 ,  G01R33/56316

摘要： A magnetic resonance imaging apparatus includes an RF coil unit which generates RF pulses toward a subject, and which receives an MR signal from the subject. Gradient magnetic field coils generate a gradient magnetic field for slice selection, a gradient magnetic field for phase encoding and a gradient magnetic field for frequency encoding, respectively. An arithmetic unit generates image data on the basis of the MR signal, and a sequence controller controls phase encoding gradient magnetic field coils in order to generate flow pulses for dephasing or rephasing the MR spin of blood flow within the subject, in the same direction as that of the phase encoding gradient magnetic field.

摘要翻译： 磁共振成像装置包括：向被检体产生RF脉冲的RF线圈单元，并从受检者接收MR信号。 梯度磁场线圈分别产生用于切片选择的梯度磁场，用于相位编码的梯度磁场和用于频率编码的梯度磁场。 算术单元根据MR信号生成图像数据，并且序列控制器控制相位编码梯度磁场线圈，以便产生用于使对象内的血流的MR自旋的相位相移或重新定位的流动脉冲，与 相位编码梯度磁场。